Daxor Corporation Expands Blood Volume Measurement Technology in New Jersey Academic Health System

Oak Ridge, TN, February 27, 2025 (GLOBE NEWSWIRE) – Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, today announced the expansion of its blood volume analysis (BVA) systems into two major hospitals within New Jersey’s largest academic health care system.

Based on current market trends and a growing pipeline of opportunities, the company anticipates maintaining its accelerated sales trajectory throughout 2025. The adoption of BVA technology at these two hospitals is a significant step, allowing their clinical teams to implement BVA analyzers, enabling real time blood volume measurement for critical care.

This advancement will help clinicians optimize fluid management, reduce hospital stays, and ultimately improve outcomes for patients with both heart failure and other critical conditions.

“The continued expansion of our market footprint is a direct result of a very effective growth strategy. The resources we have dedicated to strengthening our sales and marketing capabilities are delivering meaningful results,” stated Michael Feldschuh, CEO and President of Daxor.

“The success of Daxor’s unique approach to blood volume analysis technology plays an integral role in enhancing patient care outcomes,” he continued.

BVA-100, the only diagnostic blood test cleared by the FDA to provide safe, accurate, and objective quantification of blood volume status and composition compared to patient-specific norms, is expected to play a large role in the improvement of patient care.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is a global leader in blood volume measurement technology focused on blood volume testing innovation. Daxor developed and markets the BVA-100® (Blood Volume Analyzer). Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care.

Daxor has trials underway in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all.

For more information, please visit the company’s website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact: Bret Shapiro Sr. Managing Partner, CORE IR 1-516-222-2560 brets@coreir.com